| Completed | Retrospective Study in FFPE Samples From Younger Patients With Rhabdomyosarcoma NCT06040229 | Shandong First Medical University | — |
| Recruiting | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling NCT05857969 | Florida International University | Phase 1 |
| Completed | Ex Vivo Drug Sensitivity Testing and Mutation Profiling NCT03860376 | Florida International University | — |
| Active Not Recruiting | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT02011126 | Children's Oncology Group | Phase 2 |
| Completed | Biomarkers in Patients With Advanced Rhabdomyosarcoma NCT01668095 | Children's Oncology Group | — |
| Completed | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma NCT01614795 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma NCT01609803 | Children's Oncology Group | — |
| Completed | Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma NCT01626170 | Children's Oncology Group | — |
| Completed | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liv NCT01502410 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or NCT01305200 | Children's Oncology Group | Phase 3 |
| Completed | Intensity-Modulated Radiation Therapy in Treating Younger Patients With Lung Metastases NCT01586104 | Ann & Robert H Lurie Children's Hospital of Chicago | N/A |
| Completed | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01154816 | Children's Oncology Group | Phase 2 |
| Completed | Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients NCT01222715 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors NCT00831844 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metasta NCT00720174 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of T NCT00070109 | Children's Oncology Group | Phase 2 |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Tr NCT00309907 | Children's Oncology Group | Phase 2 |
| Completed | Ixabepilone in Treating Young Patients With Refractory Solid Tumors NCT00331643 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas NCT00101270 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatme NCT00091182 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors NCT00093821 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors NCT00077454 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive Rhabdomyosarcoma NCT00025363 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas NCT00012181 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Irinotecan in Treating Children With Refractory Solid Tumors NCT00004078 | Children's Oncology Group | Phase 2 |
| Completed | Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Sof NCT00919269 | Children's Oncology Group | — |